Advanced Therapeutics · 2020 · 42 citations · 24 references
PharmacyOncologyPharmaceuticsDrug DeliveryImmunotherapyNanoparticle Drug DeliveryCancer ImmunotherapyCancer NanomedicineNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignCancer Immunotherapy NanoparticlesCancer NanotherapyMelanoma ImmunotherapyMesoporous Silica NanomaterialsMesoporous Silica NanoparticlesMurine ModelsNanoparticle-based ImmunotherapySilica-based Nanoparticles
Stimulator of interferon genes (STING) activation by intratumoral STING agonist treatment has been recently shown to eradicate tumors in preclinical models of cancer immunotherapy, generating intense research interest and leading to multiple clinical trials. However, there are many challenges associated with STING agonist-based cancer immunotherapy, including low cellular uptake of STING agonists. Here, biodegradable mesoporous silica nanoparticles (bMSN) with an average size of 80 nm are developed for efficient cellular delivery of STING agonists. STING agonists delivered via bMSN potently activate innate and adaptive immune cells, leading to strong antitumor efficacy and prolonged animal survival in murine models of melanoma. Delivery of immunotherapeutic agents via biodegradable bMSN is a promising approach for improving cancer immunotherapy.
24
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng‐Ryong Woo, Mercedes B. Fuertes, Leticia Corrales et al. · Immunity · 2014 · 1.8K citations · Full text
Life Sciences, Immunology, Oncology +12
A STING-activating nanovaccine for cancer immunotherapy
Min Luo, Hua Wang, Zhaohui Wang et al. · Nature Nanotechnology · 2017 · 889 citations
Life Sciences, Immunology, Oncology +14